Literature DB >> 20831500

Clinical evaluation of 3D/3D MRI-CBCT automatching on brain tumors for online patient setup verification - A step towards MRI-based treatment planning.

Sune K Buhl1, Anne K Duun-Christensen, Brian H Kristensen, Claus F Behrens.   

Abstract

BACKGROUND: Magnetic Resonance Imaging (MRI) is often used in modern day radiotherapy (RT) due to superior soft tissue contrast. However, treatment planning based solely on MRI is restricted due to e.g. the limitations of conducting online patient setup verification using MRI as reference. In this study 3D/3D MRI-Cone Beam CT (CBCT) automatching for online patient setup verification was investigated.
MATERIAL AND METHODS: Initially, a multi-modality phantom was constructed and used for a quantitative comparison of CT-CBCT and MRI-CBCT automatching. Following the phantom experiment three patients undergoing postoperative radiotherapy for malignant brain tumors received a weekly CBCT. In total 18 scans was matched with both CT and MRI as reference. The CBCT scans were acquired using a Clinac iX 2300 linear accelerator (Varian Medical Systems) with an On-Board Imager (OBI).
RESULTS: For the phantom experiment CT-CBCT and MRI-CBCT automatching resulted in similar results. A significant difference was observed only in the longitudinal direction where MRI-CBCT resulted in the best match (mean and standard deviations of 1.85±2.68 mm for CT and -0.05±2.55 mm for MRI). For the clinical experiment the absolute difference in couch shift coordinates acquired from MRI-CBCT and CT-CBCT automatching, were ≤2 mm in the vertical direction and ≤3 mm in the longitudinal and lateral directions. For yaw rotation differences up to 3.3 degrees were observed. Mean values and standard deviations were 0.8±0.6 mm, 1.5±1.2 mm and 1.2±1.2 mm for the vertical, longitudinal and lateral directions, respectively and 1.95±1.12 degrees for the rotation (n=17).
CONCLUSION: It is feasible to use MRI as reference when conducting 3D/3D CBCT automatching for online patient setup verification. For both the phantom and clinical experiment MRI-CBCT performed similar to CT-CBCT automatching and significantly better in the longitudinal direction for the phantom experiment.

Entities:  

Mesh:

Year:  2010        PMID: 20831500     DOI: 10.3109/0284186X.2010.498442

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Evaluating organ delineation, dose calculation and daily localization in an open-MRI simulation workflow for prostate cancer patients.

Authors:  Anthony Doemer; Indrin J Chetty; Carri Glide-Hurst; Teamour Nurushev; David Hearshen; Milan Pantelic; Melanie Traughber; Joshua Kim; Kenneth Levin; Mohamed A Elshaikh; Eleanor Walker; Benjamin Movsas
Journal:  Radiat Oncol       Date:  2015-02-11       Impact factor: 3.481

2.  Dosimetric and geometric evaluation of the use of deformable image registration in adaptive intensity-modulated radiotherapy for head-and-neck cancer.

Authors:  R B Eiland; C Maare; D Sjöström; E Samsøe; C F Behrens
Journal:  J Radiat Res       Date:  2014-06-06       Impact factor: 2.724

Review 3.  A review of substitute CT generation for MRI-only radiation therapy.

Authors:  Jens M Edmund; Tufve Nyholm
Journal:  Radiat Oncol       Date:  2017-01-26       Impact factor: 3.481

4.  Assessment of positional reproducibility in the head and neck on a 1.5-T MR simulator for an offline MR-guided radiotherapy solution.

Authors:  Yihang Zhou; Jing Yuan; Oi Lei Wong; Winky Wing Ki Fung; Ka Fai Cheng; Kin Yin Cheung; Siu Ki Yu
Journal:  Quant Imaging Med Surg       Date:  2018-10

5.  Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study.

Authors:  Tufve Nyholm; Joakim Jonsson; Karin Söderström; Per Bergström; Andreas Carlberg; Gunilla Frykholm; Claus F Behrens; Poul Flemming Geertsen; Redas Trepiakas; Scott Hanvey; Azmat Sadozye; Jawaher Ansari; Hazel McCallum; John Frew; Rhona McMenemin; Björn Zackrisson
Journal:  Radiat Oncol       Date:  2013-05-24       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.